Participated · Equity · Sep 2021

5ireChain is described as a cutting-edge blockchain platform that focuses on AI, decentralized perpetual exchanges (Perp DEX), and real-world assets (RWA). The company is running a $10 million grant program intended to nurture projects within its ecosystem. GotBit Hedge Fund has made a substantial seven-figure investment to support 5ireChain and its grant initiatives. The articles frame the investment as a strategic endorsement of 5ireChain’s vision and its potential to drive blockchain innovation. Exact financial details of the investment were not disclosed in the coverage. The reporting emphasizes the partnership’s role in accelerating development and adoption across AI, Perp DEX, and RWA use cases. 5ire is a level-1 blockchain that positions itself as a sustainable chain built around a proprietary validating mechanism called 'proof of benefit', aligned with the 17 UN Sustainable Development Goals and ESG parameters. Founded in August 2021 by Pratik Gauri, Prateek Dwivedi and Vilma Mattila, the company is currently pre-revenue but expects to start generating revenue from November and targets $1 billion in revenue within three years. 5ire has invested prior capital into talent acquisition, technology development, patent filings, and sales and marketing. The startup currently has 105 employees, about 70% of whom are based in India, and plans to grow headcount to 150 while extending its footprint across Asia, North America and Europe with India as its hub. The company raised a $21 million seed round last October at a $110 million valuation and reported it still held roughly 49% of that seed capital. Following the recent Series A, 5ire is valued at $1.5 billion and has been reported as India’s 105th unicorn. 5ireChain positions itself as a fifth-generation, tier-one smart contract chain and distributed computing platform focused on sustainability. Its core technology, “Proof of 5ire,” integrates sustainability at the consensus and governance level by economically rewarding companies and individuals for sustainable practices. The platform emphasizes developer friendliness with features the company cites such as no-code smart contracts, simplified addresses, and customized functionalities for Web3 solutions. Leadership includes co-founder and CEO Pratik Gauri and co-founder and CBO Vilma Mattila, and the project frames its mission around accelerating the UN 2030 Agenda for Sustainable Development. Financially, 5ireChain completed a $190k angel round (closed in 28 minutes) and a $1M private sale round (completed in 72 hours) and said a second private sale of $1.5M will open to institutional investors. The company stated the funds will be used to develop its technology and expand the team.

Participated · Series A · Dec 2020

PathologyWatch operates an end-to-end digital dermatopathology platform that integrates laboratory information systems, scanners, a digital viewer, and EMR reporting to give clinics 24/7 access to digital slides and expert dermatopathologists. The company’s core product streamlines workflows for dermatology clinics and labs, enabling faster diagnoses and broader insurance coverage. PathologyWatch is positioning its platform to improve access and equity in dermatopathology while reducing pathology costs. With the new funding, the company plans further research into skincare diagnostics and AI to enhance its diagnostic capabilities. PathologyWatch is expanding operations nationwide and will add new labs in Texas, Florida, and Arizona to support growing volume. CEO and cofounder Dan Lambert emphasizes the company’s role in digitally transforming dermatopathology and improving patient care. PathologyWatch is a Salt Lake City, UT‑based provider of digital dermatopathology services that offers fully interfaced EMR reporting and around‑the‑clock access to digital slides. The company’s solution gives dermatology clinics, hospitals and laboratories access to top‑tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR. PathologyWatch aims to improve operational efficiency by speeding up workflow and enhance patient outcomes via its expert professional team and partner laboratory services. Led by CEO and co‑founder Dan Lambert, the company has raised over $10M in total capital to date. PathologyWatch plans to use new funding to develop its digital dermatopathology offerings, scale its laboratory system and extend artificial intelligence research across various cancer lines to support larger clients and further technological progress. PathologyWatch builds intuitive, easy‑to‑implement digital dermatopathology solutions that digitize pathology workflows and provide EMR‑integrated reporting and 24/7 access to digital slides. The company offers access to top dermatopathologists and lets clients interpret and bill for cases, with a primary focus on outpatient clinics. PathologyWatch has deployed supervised AI in dermatopathology and reports a live clinical implementation in Australia that can generate full reports. It will use the Series A proceeds to strengthen outreach to dermatology clinics nationwide, including plans to triple its sales force over 12 months, expand marketing, and implement a channel partner strategy. The funding will also support continued development of technology and supervised AI for various cancer lines.

Participated · Series A · Nov 2019

Flavourworks develops live-action interactive experiences that blend filmed performances with game-style decision-making via its patent-pending cross-platform Touch Video technology. The studio’s first title, Erica, is published by Sony Interactive Entertainment and is available on PlayStation 4, with mobile launches planned. Flavourworks’ Touch Video lets players interact directly with filmed scenes using a controller touchpad or a mobile screen to produce nuanced, tactile story interactions. The company was founded in 2015 by Jack Attridge and Pavle Mihajlovic on London’s Silicon Roundabout. Flavourworks is expanding its studio and technology to build a pipeline of new interactive titles. The recent financing is intended to deepen the technology and support content production and global distribution efforts.

Participated · Seed · Jan 2018

Medumo provides automated patient-preparation software that sends procedure reminders and mobile-optimized instructions via text message, sometimes including images and video. The platform delivers step-by-step preparation guidance and links to patients to improve readiness for hospital procedures. In a clinical study of more than 4,000 patients the company reported reducing no-shows by over 50% and improving preparedness by over 40%. For hospitals this resulted in roughly $0.5 million to $1 million in annual revenue recovered from procedures that would have been canceled. Medumo is currently working with 13 hospitals and is focused on seven specialties; it plans to use new funding to partner with more institutions and expand beyond those specialties. The company has collaborated with Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Brigham and Women's through its participation in the 2018 PULSE@MassChallenge accelerator.